Solid Biosciences to Participate at Upcoming Investor Conferences

SLDB 11.26.2024

Full Press ReleaseSEC FilingsOur SLDB Tweets

About Gravity Analytica

Recent News

  • 01.21.2025 - Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia
  • 01.15.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.15.2025 - Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines

Recent Filings

  • 01.13.2025 - 4 Statement of changes in beneficial ownership of securities

CHARLESTOWN, Mass.,Nov. 26, 2024(GLOBE NEWSWIRE) --Solid Biosciences Inc.(Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences:

  • Citi’s 2024 Global Healthcare Conference –Miami, FLBo Cumbo, President and CEO, will participate in a panel discussion titled “Neuromuscular Disorders” onWednesday, December 4, 2024, at1:00 p.m. ET.
  • Piper Sandler 36thAnnual Healthcare Conference –New York, NYMr. CumboandGabriel Brooks, M.D., Chief Medical Officer, will participate in a fireside chat onThursday, December 5, 2024, at9:30 a.m. ET.

Live webcasts of the Citi panel discussion and Piper Sandler fireside chat will be available on the Events page of the Investors section of the Company website or byclicking here. A webcast replay will be archived for 30 days on the Events page.

Institutional investors interested in meeting with management during the conference may reach out to their Citi or Piper Sandler representatives.

AboutSolid BiosciencesSolid Biosciencesis a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visitwww.solidbio.com.

Solid Biosciences Investor Contact:Nicole AndersonDirector, Investor Relations and Corporate CommunicationsSolid Biosciences Inc.investors@solidbio.com

Media Contact:Glenn SilverFINN Partnersglenn.silver@finnpartners.com

Primary Logo

Source: Solid Biosciences Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com